Ebm.V
EBM.V operates in the pharmaceuticals industry, focusing on the development and commercialization of medical products and services.
Business. EBM.V operates in the pharmaceuticals industry, focusing on the development and commercialization of medical products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
EBM.V operates in the pharmaceuticals industry, focusing on the development and commercialization of medical products and services.
EBM.V's capital structure is highly leveraged, with total liabilities of CAD 1.85 billion and total equity of CAD -1.63 billion, resulting in a negative debt-to-equity ratio of -0.05. The company's liquidity position is weak, as indicated by a current ratio of 0.02, suggesting significant short-term financial stress. Free cash flow is negative at CAD -287.81 million, further highlighting the company's inability to generate sufficient cash from operations to fund its activities.
Profitability metrics show a stark contrast to industry norms. Gross profit of CAD 550.99 million is positive, but operating income is a loss of CAD 332.77 million, and net income is also a loss of CAD 332.77 million. Return on equity is 20.42%, which is unusually high given the negative equity position, and return on assets is -1.52%, indicating poor asset utilization. These figures suggest the company is not generating returns that meet industry expectations.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits the company's ability to offset losses in one area with gains in another.
Growth trajectory is negative, with no disclosed revenue growth in the current fiscal year. The company is expected to continue facing financial challenges in the next fiscal year, with no clear path to profitability or improved liquidity. Historical revenue trends show a decline, and there are no indications of a turnaround in the near term.
Risk factors include high liquidity risk due to negative working capital and a negative net cash position after subtracting total debt. The company's dilution potential is low, but the negative equity position and high leverage increase the risk of further dilution if the company needs to raise additional capital. No recent events or filings have been disclosed that would indicate a change in the company's financial strategy or operations.
- EBM.V has a highly leveraged capital structure with a negative equity position.
- The company is not generating positive operating or net income, indicating poor profitability.
- Liquidity is critically low, with a current ratio of 0.02 and negative free cash flow.
- Revenue is concentrated in a single segment, increasing exposure to market-specific risks.
- The company is expected to continue facing financial challenges in the next fiscal year.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- EBM.V Market data — financials · 2026-05-27